INSIGHTS ON PHARMACEUTICAL PRODUCTION
-
![Silverson]( "How To Produce A Fine, Stable Emulsion With High Shear Mixing")
How To Produce A Fine, Stable Emulsion With High Shear MixingAn emulsion is a mixture of two or more immiscible liquids – one being oil based and the other water based, or “aqueous.” They are described as “immiscible” liquids because they cannot easily be mixed together without separating. This video demonstrates how adding an emulsifier and using a high shear rotor/stator mixer can uniformly disperse the ingredients.
-
![Thermo]( "Thermo Fisher Scientific North America Single-Use Technologies Capacity Expansion")
Thermo Fisher Scientific North America Single-Use Technologies Capacity ExpansionThermo Fisher Scientific is expanding our single-use manufacturing network globally. Some of the largest investments are taking place at our existing Logan, Utah, and Millersburg, Pennsylvania, sites. We are adding space for clean rooms for the manufacturing and assembly of Thermo Scientific BioProcess Containers and fluid transfer assemblies, investing in 2D and 3D chamber manufacturing equipment, and harmonizing our quality systems and processes.
-
![Batch Mixer]( "Scott Turbon Batch Mixing")
Scott Turbon Batch MixingDiscover the benefits of Scott Turbon Mixer technology for batch mixing. From smaller in-tank batches to large multi-tank platforms.
-
![iStock-1147277117-lab-transfer]( "Monoclonal Cell Line Development: Clonality Tracing")
Monoclonal Cell Line Development: Clonality TracingMonoclonal cell lines are a necessary component in several aspects of the drug discovery process including recombinant protein expression and monoclonal antibody development. Manual screening methods can be labor intensive and time consuming.
-
Lipid Nanoparticles Are Having A Breakout Moment9/3/2020
After more than 25 years of commercial use with almost 20 parenteral drug products, lipid nanoparticles (LNPs) are having a breakout moment. While LNPs are now a proven drug delivery technology to penetrate target cells and ensure release for reliable systematic or local delivery, their true market potential as a gene and cell therapy enabler has only become clear to many since COVID-19.
-
Successful Techniques For Progressing Biotherapeutic Candidates From Late Discovery To The Clinic1/26/2021
The reality is that many initially promising biotherapeutic candidates never make it to commercialization. It is estimated that only 1 in 1000 preclinical candidates reach the commercial market. Why does this happen? There are many that fail due to lack of efficacy or safety, but there are also candidates that fail due to stability, aggregation, and other issues related to cell line or process issues. In our latest white paper, we help you to prepare for a successful transition to bring your drug candidate from discovery to the clinic.
-
Scott Turbon Hydraulic Ram Mixer3/5/2021
Move mixer from one batch to the next batch in seconds with no downtime, Scott Turbon Mixer Hydraulic Ram.
-
End-To-End Thinking During Drug Product Development10/7/2020
In this article, Dr. Kashif Ghaffar, process validation pharmacist at Pfizer’s Freiburg facility, discusses what needs to be considered during product development in preparation for commercial manufacture.
-
Fareva HPAPI Building Construction9/23/2019
In August 2018, Fareva completed the construction of their $30M new HPAPI facility at the Fareva La Vallée site. In this video you will see a time lapse view of the construction of the highly potent API facility.
PHARMACEUTICAL PRODUCTION SOLUTIONS
-
![Quadro ytron]( "Used Quadro Ytron Blender: Model ZC1")
Used Quadro Yton blender, model ZC1, stainless steel construction, nominally rated 3-12 gpm, up to 30#/minute powder capacity, with powder funnel, driven by 7.5 hp, xp motor, 1" inlet/outlet, skid mounted with Idex rotary lobe pump, model 0300, Quadro serial# ZC1-0311, built 2009.
-
![Capsules]( "Commercial Drug Manufacturing Services – Pharma Solid Oral Dosage")
To complement Ropack Pharma Solutions’ drug development and packaging technologies, we provide clinical and commercial drug manufacturing services for solid oral dosage.
-
![high-potent-compound-handling]( "Highly Potent API Handling")
Pii operates over 360,000 square feet of state-of-the-art pharmaceutical development and manufacturing space, all located on one campus in Hunt Valley, MD. This includes over 70 flexible, manufacturing suites, several with the required containment controls for handling potent compounds and hormones, as well as a dedicated suite for the production of soft gel capsules. Licensed to manufacture DEA Schedule I-V products, with capabilities for both oral delivery and parenteral dosage forms, Pii has the depth to support development, clinical and commercial requirements. Facilities are cGMP qualified and include dedicated formulation development centers for solid oral, liquid and sterile products.
-
![Dressing Sauce Systems]( "Scott Turbon Dressing And Sauce Systems")
The next step in production efficiency is the Scott Turbon® Dressing and Sauce System. This multi-functional processing environment is designed and built to seamlessly combine batch production and raw material staging.
-
Promega has 40 years of experience in developing and manufacturing amplification reagents to suit our customers’ specific needs. We are a primary manufacturer of amplification components. Therefore, we control all aspects of product manufacturing, from raw materials through finished product, eliminating supply-chain uncertainty. Our PCR master mix portfolio covers a spectrum of PCR performance capabilities for endpoint, multiplex, real-time, GC-rich, and inhibitor-resistant amplifications.
